益气补脑治疗脑梗死后丘脑痛的临床研究

Clinical Study of the Thalamic Pain Treated with Combined Medicine Based on Brain-tonifying and Qiboosting

目的观察益气补脑治疗脑梗死后丘脑痛的临床疗效和安全性。方法 42例患者随机分成治疗组和对照组两组各21例。两组均在脑梗死二级防治指南治疗基础上进一步治疗。对照组予卡马西平治疗。治疗组进一步分成阳气虚和阴气虚亚组,分别给予参附注射液、奥德金和参麦注射液、奥德金静脉滴注治疗。14 d为1个疗程。用视觉模拟评分法(VAS)和美国安德森肿瘤中心疼痛评估表(MD疼痛值)进行评定,记录治疗前后VAS和MD疼痛值;并且在治疗前后检测血常规、肝肾功能、出凝血功能。结果两组治疗后VAS评分、MD评分与治疗前比较,均有明显下降(P<0.01或P<0.05),且治疗组VAS评分低于较对照组(P<0.05)。治疗组有效率与对照组有效率差别不大。但治疗组临床治疗显愈率优于对照组。治疗后,治疗组5例临床症状消失,达到临床治愈。治疗2周后治疗组停药,跟踪疗效8周,症状无反跳。对照组则无法停药,否则症状反跳明显。治疗前后未见明显严重不良反应。结论补气益脑方案治疗脑梗死后丘脑痛安全并有显著疗效。

Objective： To study the effectiveness and safety for thalamic pain after cerebral infarction treated with combined medicine based on brain-tonifying and qi-boosting. Methods： A total of 42 patients with thalamic pain were randomized equally into the intervention group and the control group. After managed in accordance with the Guidelines for the Secondary Prevention of Ischemic Stroke,the patients of both groups received further treatment. The patients of control group were given carbamazepine. The patients of intervention group were further di-vided into subgroup of yang-qi deficiency and of yin-qi deficiency. The patients of yang-qi deficiency subgroup were intravenously administered with injection Shenfu,and Deproteinised Calf Blood Injection DCBI（Adegold）;While the patients of yin-qi deficiency subgroup with injection Shenmai. Each group was treated for 14 days. The effects were evaluated with the visual analogue scale（VAS） and pain evaluated scale of Anderson Cancer Center,Pain Evaluation value（PEV）,respectively. Meanwhile,before and after the treatment,the blood and urine routine,liver and kidney function,and coagulation tests were performed for the patients of both groups. Results： The VAS score and PEV decreased significantly after treatment in both the control group（P 〈0.05） and the intervention group（P 〈0.01）;The decreases of which of the intervention group are more obviously than which of the control group（P 〈0.05）. 10 patients in the intervention group are cured;While no patient in the control group is cured（P 〈0.01）. Conclusion： The combined therapy is highly effective and safe in managing thalamic pain.